CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OncoMark Ltd is creating OncoMasTR, a breast cancer prognostic test that helps determine the necessity of chemotherapy for early-stage patients. This assay is designed to be cost-effective and user-friendly, enhancing clinical decision-making.
OncoMark Ltd are developing a novel, game-changing breast cancer prognostic assay, called OncoMasTR, which has the potential to transform clinical practice and patient care.
OncoMasTR will help clinicians to decide which patients should receive chemotherapy for early stage breast cancer, which is a pressing clinical and economic issue worldwide.
OncoMasTR is more cost-effective than competitor assays, demonstrates superior performance clinically, generates a user-friendly binary (yes/no) output…
ONCOMARK LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
